Linezolid pharmacokinetics in patients with acute renal failure undergoing continuous venovenous hemodiafiltration

Journal of Clinical Pharmacology

Volumn 52, Issue 9, 2012, Pages 1430-1435

  Carcelero, Esther ^a   Soy, Dolors ^a,b   Guerrero, Laura ^a,b   Poch, Esteban ^a,b   Fernandez, Javier ^b,c   Castro, Pedro ^d   Ribas, Jose ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Liver ICU   (Spain)

^d Institut Clínic de Medicina i Dermatologia   (Spain)

^e NONE

Author keywords

Acute renal failure; continuous hemodiafiltration; ICU; linezolid; pharmacokinetics

Indexed keywords

CEFOTAXIME; LINEZOLID;

ACUTE KIDNEY FAILURE; ADULT; AGED; APACHE; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; STEADY STATE; VENTILATOR ASSOCIATED PNEUMONIA;

ACETAMIDES; ACUTE KIDNEY INJURY; AGED; ANTI-INFECTIVE AGENTS; CRITICAL ILLNESS; FEMALE; HEMODIAFILTRATION; HUMANS; LISTERIA MONOCYTOGENES; LISTERIOSIS; MALE; MENINGITIS, PNEUMOCOCCAL; MIDDLE AGED; OXAZOLIDINONES; SHOCK, SEPTIC;

EID: 84866042182     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011417717     Document Type: Article

References (19)

1. Clermont G, Acker CG, Angus DC, Sirio CA, Pinsky MR, Johnson JP. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int. 2002 ; 62: 986-996
2. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005 ; 294: 813-818
3. Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med. 2008 ; 36: 610-617
4. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998 ; 32: 362-375
5. Vanholder R, Van Biesen W, Lameire N. What is the renal replacement method of first choice for intensive care patients?. J Am Soc Nephrol. 2001 ; 12 (Suppl 17). S40-43
6. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007 ; 46: 997-1038
7. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003 ; 51 (Suppl 2). ii17-25
8. Gentry-Nielson MJ, Olsen KM, Preheim LC. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2002 ; 46: 1345
9. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003 ; 42: 1411-1423
10. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003 ; 42: 1129-1140
11. Mauro LS, Peloquin CA, Schmude K, Assaly R, Malhotra D. Clearance of linezolid via continuous venovenous hemodiafiltration. Am J Kidney Dis. 2006 ; 47: e83-86
12. Kraft MD, Pasko DA, DePestel DD, Ellis JJ, Peloquin CA, Mueller BA. Linezolid clearance during CVVHDF: a case report. Pharmacotherapy. 2003 ; 23: 1071
13. Guerrero L, Sarasa M, López Y, Soy D. Measuring linezolid in biological fluids using high efficiency liquid chromatography. Farm Hosp. 2010 ; 34: 27-31
14. Department of Health and Human Services, US Food and Drug Administrationhttp://www.fda.gov/cder/guidance/4252fnl.pdf. Accessed September 1, 2010. http://www.fda.gov/cder/guidance/cmc3.pdf. Accessed September 1, 2010. http://www.fda.gov/cber/gdlns/methval.pdf. Accessed September 1, 2010.
15. The European Agency for the Evaluation of Medicinal Products (Europe). http://www.emea.europa.eu/htms/vet/vetguidelines/quality.htm. Accessed September 1, 2010. http://www.emea.europa.eu/pdfs/human/ich/038195en.pdf. Accessed September 1, 2010.
16. Bauer LA, Gibaldi M. Computation of model-independent pharmacokinetic parameters during multiple dosisng. J Pharm Sci. 1983 ; 72: 978-979
17. Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther. 2005 ; 27: 599-608
18. Tegeder I, Bremer F, Oelkers R, et al. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother. 1997 ; 41: 2640-2645
19. Susla GM. The impact of continuous renal replacement therapy on drug therapy. Clin Pharmacol Ther. 2009 ; 86: 562-565